Veralto Corporation

The forensic scores point in a mixed but mostly reassuring direction. The Beneish M-Score is -2.472, below -1.78 and not in the elevated zone. The Beneish model is a screening tool for possible earnings manipulation, so a value outside the elevated zone is a screening result, not a guarantee that the accounts are clean. The Altman Z″-Score is 3.74, in the safe zone, which is a rough gauge of balance-sheet distress risk. The Piotroski F-Score is 6 of 8 computable signals. It is a checklist of profitability, leverage and efficiency tests, and the two computable signals not passed are not identified in the data, so readers may want to check the full financial statements in the 10-K to see which ones. Operating cash flow of $1.08 billion was 1.15 times net income of $940 million, meaning reported cash generation ran ahead of accounting profit in 2025. Capital allocation is visible in the filings. The board authorized up to $750 million of share repurchases on November 25, 2025, and Veralto repurchased 3,224,855 shares in the quarter ended April 3, 2026, leaving $450 million under the program. Shareholders' equity rose to $3.1 billion from $2.04 billion. The CEO adopted a Rule 10b5-1 plan covering up to 21,292 shares of common stock, running through February 24, 2027. The 10-Q states that disclosure controls were effective and reports no material change in internal control over financial reporting. The 10-K risk factors also cover tariffs, competition, goodwill impairment and indebtedness covenants, which a reader can weigh against these results.

Catalyst.Per the 2025 annual figures, revenue reached $5.5 billion, up 6.0% from $5.19 billion in 2024, and operating income rose to $1.28 billion from $1.21 billion. Operating cash flow climbed to $1.08 billion from $875 million. The 10-K says recurring sales were approximately 61% of total sales in 2025, supported by a large installed base of instruments that drive consumables and software sales. The two segments are Water Quality (Hach, Trojan Technologies, ChemTreat) and Product Quality & Innovation (Videojet, Linx, Esko, X-Rite, Pantone). The excerpts provided do not include the MD&A discussion of segment-level drivers, so the specific sources of this growth cannot be fully attributed here.

Hidden risk.The easiest item to miss is the 2026 Restructuring Program approved April 27, 2026. Total charges are expected to range from $85 million to $105 million, with $45 million to $55 million in cash during 2026, and the program is expected to be substantially completed by the end of 2028. A new risk factor warns that restructuring and cost reduction reduce available talent and resources, could slow product improvements, and could limit production increases if demand rises. Separately, long-term debt was $1.97 billion at year-end 2025 versus $2.6 billion a year earlier, and the 10-K flags covenant compliance and credit-rating risk on that indebtedness. Readers may want to weigh how cost cutting and acquisition integration could affect the margin gains reported in 2025.